Sigma-Aldrich — Shareholder Meeting (May 2010)
26 slides from Sigma-Aldrich's shareholder meeting presentation, May 4, 2010
Slide 1: Sigma-Aldrich Corporation 2010 Shareholders Meeting
Sigma-Aldrich Corporation 2010 Shareholders Meeting Enabling Science to Improve Quality of Life May 4, 2010 Exhibit 99.1
Slide 2: Cautionary Statement
Cautionary Statement Our presentation today will include forward-looking statements relating to the Company’s future performance, goals, strategic actions and initiatives and similar intentions and beliefs, including expectations, goals, beliefs, intentions and the like regarding future sales, earni
Slide 3: Agenda
Agenda 2009 Business and Financial Highlights Our Company Plans for Growth First Quarter Results and Full Year 2010 Outlook
Slide 4: Our Objectives
Mission – Enabling science to improve the quality of life Vision – To be the trusted global partner of choice for our customers Objective – To deliver sustainable above-market growth and create value for our Employees, Customers and Shareholders by building on our core capabilities and leveraging ou
Slide 5: Diversified approach to yield consistent returns
Diversified approach to yield consistent returns Who is Sigma-Aldrich? Delivering Value Through a Balanced Portfolio
Slide 6: Who is Sigma-Aldrich?
70% Research Consumables 30% Fine Chemicals & Services • Research Business • Manufacturing (SAFC) A leading Life Science company enabling researchers and manufacturers to improve the quality of life Who is Sigma-Aldrich? • Customers – Academia – Pharma & Biotech – Industrial – Hospitals – Testing La
Slide 7: 2009 Financial Highlights
Strong performance in a challenging economy 2009 Financial Highlights Record Year for Earnings and Free Cash Flow
Slide 8: Historical Performance – Profitable Sales Growth
35 years of continuous EPS growth Historical Performance – Profitable Sales Growth • Demonstrated historic performance • Robust business model
Slide 9: Historical Performance – Shareholder Returns
• Returns Consistently deliver superior returns Historical Performance – Shareholder Returns • Sustained high returns • Shareholder returns outperformed peers and broad market indices Peers: Affymetrix, Cambrex, Dionex, Illumina, Life Technologies, Millipore, Qiagen, Techne, Thermo-Fisher, Waters $1
Slide 10: Key Business Highlights
Supporting the advancement of science, education, innovation, thought leadership and environmental sustainability 2009 Highlights Key Business Highlights • Research Biotech growth drivers – Innovative new antibody products – Regenerative medicine • Fine Chemicals (SAFC) benefits from sale of H1N1 va
Slide 11: Awards and Recognitions
• Research Biotech • SAFC • Sigma - Aldrich 2009 Highlights Awards and Recognitions • Top 5 Innovations of 2009 for knockout rat – The Scientist magazine • 2009 North America Healthcare Innovation Award – Frost & Sullivan • 2009 CIO 100 award for innovative web research tool, Your Favorite Gene powe
Slide 12: Commitment to Corporate Citizenship
• Team 2009 Highlights Commitment to Corporate Citizenship Sigma-Aldrich Celebrates 5th Anniversary • 1,300 employees participated in 23 events • Introduced two new sites to the program – Castle Hill, Australia – Oakville, Canada • Employees gave back over 4,200 hours of service • Events: – Habitat
Slide 13: First Quarter 2010 Financial Results vs. Prior Year
YEAR-OVER-YEAR Diluted EPS, excluding restructuring costs were $0.84, 24% higher than the same period last year First Quarter 2010 Financial Results vs. Prior Year Diluted EPS Net Income Sales $572 $100 $0.81 Q1 2010 (in millions, except EPS) 10 % 19 % 19 % As Reported Free Cash Flow $133 55 % 4 % 1
Slide 14: 2010 Outlook
2010 Outlook Free Cash Flow Reported EPS Organic Revenue Growth $3.05 to $3.20 > $350 million Mid single digits
Slide 15: Objectives: 2010-2014
Strategic actions build sustainable value Five-Year Financial Targets Incremental Impact Objectives: 2010-2014 Top line organic growth (normal economic conditions) 7-8% Expand cumulative operating margins by 2014 200-300 bpts Cumulative free cash flow (five years) > $2 Billion • Deliver above-market
Slide 16: Plan to Achieve Objective: Top Line Growth Initiatives
Initiatives 4% incremental contribution to top line growth Plan to Achieve Objective Top Line Growth Initiatives Innovation ABC M Focus Analytical Expand into attractive areas of detection and analysis Biology Increase focus on biology Expand traditional product portfolio and build new targeted plat
Slide 17: Impact of Top-Line Growth
Impact of Top-Line Growth Initiatives to achieve above market growth rates
Slide 18: Plan to Achieve Objective: Expand Operating Margins
Leverage core competencies through targeted initiatives to create value Plan to Achieve Objective Expand Operating Margins Portfolio optimization Capacity utilization Focus on differentiation Sourcing knowledge Competitive pricing strategies Operational excellence Optimize supply chain Leverage proc
Slide 19: Profitability Drivers
Net 200-300 basis point improvement in operating margin over five years Profitability Drivers Impact of Initiatives
Slide 20: Future Uses of Cash
Expect free cash flow to be in excess of $2 billion over next five years Future Uses of Cash 2010 and Beyond • Fund organic growth through technology, partnerships, licensing and go-to-market investments • Fund inorganic growth • Cash dividends • Share repurchases • Debt reduction
Slide 21: Investments for Growth
Infrastructure remains a key differentiator as we drive demand • Investments for Growth Shanghai, China • New 35,000 sq. ft. distribution and warehousing center
Slide 22: Investments for Growth
Infrastructure remains a key differentiator as we drive demand • • Investments for Growth Shanghai, China • New 35,000 sq. ft. distribution and warehousing center Jerusalem, Israel • Large-scale fermentation plant to produce biologics
Slide 23: Investments for Growth
Infrastructure remains a key differentiator as we drive demand • • • Investments for Growth Shanghai, China • New 35,000 sq. ft. distribution and warehousing center Jerusalem, Israel • Large-scale fermentation plant to produce biologics Carlsbad, California • Capacity expansion to produce viral vacc
Slide 24: Investments for Growth
Infrastructure remains a key differentiator as we drive demand • • • • Investments for Growth Shanghai, China • New 35,000 sq. ft. distribution and warehousing center Jerusalem, Israel • Large-scale fermentation plant to produce biologics Carlsbad, California • Capacity expansion to produce viral va
Slide 25: Compelling investment opportunity
Compelling investment opportunity Sigma-Aldrich Uniquely Positioned for Value Creation Unrivaled scientific knowledge and unsurpassed service Diversified portfolio: products, customers Expanding global footprint History of profitable growth Strong financial position and cash flow Plans to enhance gr
Slide 26: Sigma-Aldrich Corporation – Questions?
Sigma-Aldrich Corporation 2010 Shareholders Meeting Enabling Science to Improve the Quality of Life Questions ?